Get the Stockscreener App
2.85
1.72%
-0.05
After Hours:
2.81
-0.04
-1.40%
Mei Pharma Inc stock is traded at $2.85, with a volume of 11,452.
It is down -1.72% in the last 24 hours and down -8.06% over the past month.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
See More
Previous Close:
$2.90
Open:
$2.9
24h Volume:
11,452
Relative Volume:
0.12
Market Cap:
$18.92M
Revenue:
$105.38M
Net Income/Loss:
$19.84M
P/E Ratio:
-0.6156
EPS:
-4.63
Net Cash Flow:
$-53.02M
1W Performance:
-2.73%
1M Performance:
-8.06%
6M Performance:
-28.75%
1Y Performance:
-59.34%
1-Day Range:
$2.81
$2.90
1-Week Range:
$2.81
$3.00
52-Week Range:
$2.7293
$7.8734
Mei Pharma Inc Stock (MEIP) Company Profile
Name
Mei Pharma Inc
Sector
Industry
Phone
858-369-7100
Address
11455 EL CAMINO REAL, SAN DIEGO, CA
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-25-22 | Downgrade | Jefferies | Buy → Hold |
| Mar-25-22 | Downgrade | Stifel | Buy → Hold |
| Mar-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Feb-03-22 | Initiated | Jefferies | Buy |
| Sep-22-20 | Initiated | Alliance Global Partners | Buy |
| May-29-20 | Initiated | SunTrust | Buy |
| Dec-20-18 | Initiated | H.C. Wainwright | Buy |
| Jul-27-18 | Upgrade | Stifel | Hold → Buy |
| Jul-13-18 | Initiated | SunTrust | Buy |
| Apr-18-16 | Reiterated | Wedbush | Neutral |
| Mar-23-15 | Downgrade | ROTH Capital | Buy → Neutral |
| Dec-18-14 | Reiterated | ROTH Capital | Buy |
| Oct-16-14 | Reiterated | ROTH Capital | Buy |
| Jul-08-14 | Resumed | Brean Capital | Buy |
| Oct-22-13 | Reiterated | Stifel | Buy |
| Apr-15-13 | Initiated | Stifel | Buy |
View All
Mei Pharma Inc Stock (MEIP) Latest News
Histone Deacetylase 2 Industry Forecast (2024-2034) Under Inflation - Apiculture Market: Report ...
Myelodysplastic Syndrome Drugs Market Research Explores Size, Market Competitive Landscape, Business Growth... - WhaTech
Chronic Lymphocytic Leukemia Treatment Market Advancements Highlighted by Comprehensive Analysis, Advanceme... - WhaTech
Follicular Lymphoma Treatment Market Insights Discussed Regarding Size, Trends, and Overview Report 2024-2033 - WhaTech
MEI Pharma reviews strategic options amid fiscal changes - Investing.com
MEI Pharma Reports Fiscal Year End 2024 Cash Position - The Bakersfield Californian
MEI Pharma Reports Fiscal Year End 2024 Cash Position - StockTitan
Expanding the Bispecific Antibody Market from CAR-Ts to Drive Follicular Lymphoma's Future | DelveInsight - PR Newswire UK
Biopharma Layoff Tracker 2024: Oncternal, Biosense Webster, Charles River Laboratories and More Cut Staff - BioSpace
LPL Financial (NASDAQ:LPLA) Research Coverage Started at Wells Fargo & Company - Defense World
Los Angeles Capital Management LLC Reduces Stake in Martin Marietta Materials, Inc. (NYSE:MLM) - Defense World
Histone Deacetylase Inhibitors Report 2024, Industry Analysis And Overview By 2033 - WhaTech
Post-Polycythemia Vera Myelofibrosis (PPV-MF) Industry - openPR
MEIP (MEI Pharma) Dividends per Share : $0.00 (TTM As of Mar. 2024) - GuruFocus.com
Rx Rundown: Vantive, Gilead Sciences, Halda Therapeutics and more - MM+M Online
MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - StockTitan
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
GreenWood Investors First Half 2024 Letter - Seeking Alpha
MEI Pharma (MEIP) – Research Analysts’ Recent Ratings Updates - Defense World
Game-Changing BCL-2 Inhibitors Set to Revolutionize Cancer Treatment Market | DelveInsight - GlobeNewswire
MEI Pharma announces executive departures and strategic shifts - Investing.com
MEI Pharma announces executive departures and strategic shifts - Investing.com India
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com Canada
MEI Pharma announces executive departures and strategic shifts By Investing.com - Investing.com UK
MEI Pharma Explores Strategic Shifts, Leadership Changes - TipRanks
Non-Hodgkin's Lymphoma Therapeutics Market to Reach USD 18.6 Billion by 2034: Fuelled by New Drugs and Targeted Therapies | Latest Report by TMR - PR Newswire
MEI Pharma Explores Strategic Options, Halts Drug Development - TipRanks
Acadian Asset Management LLC Sells 13,658 Shares of MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
Biopharma Layoff Tracker 2024: Anokion, GlycoMimetics, Relay and More Cut Staff - BioSpace
MEI Pharma (NASDAQ:MEIP) Receives New Coverage from Analysts at StockNews.com - Defense World
StockNews.com Initiates Coverage on Perficient (NASDAQ:PRFT) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Brookline Capital Management - Defense World
State Board of Administration of Florida Retirement System Increases Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) - Defense World
Blair William & Co. IL Takes Position in BRC Inc. (NYSE:BRCC) - Defense World
Avantax Advisory Services Inc. Buys Shares of 8,840 Dimensional World ex U.S. Core Equity 2 ETF (NYSEARCA:DFAX) - Defense World
MEI Pharma (NASDAQ:MEIP) Downgraded by Laidlaw - Defense World
Does MEI Pharma Inc (NASDAQ: MEIP) Still Need To Convince Analysts? - Stocks Register
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1 - Marketscreener.com
MEI Pharma stock downgraded amid strategic review and shutdown risk By Investing.com - Investing.com Canada
MEI Pharma initiates strategic review and layoffs By Investing.com - Investing.com Australia
MEI Pharma initiates strategic review and layoffs - Investing.com
MEIP Stock sees a Significant Surge Amidst Strategic Evaluation - BP Journal
MEI Pharma Announces Executive Changes and Strategic Overhaul - TipRanks
Finance Watch: A Year After Investors Denied Infinity Merger, MEI Considers Strategic Alternatives - Scrip
MEI Pharma initiates strategic review and layoffs By Investing.com - Investing.com Canada
MEI Pharma (NASDAQ:MEIP) Stock Quotes, Forecast and News Summary - Benzinga
MEI Pharma Inc (MEIP) Stock: A Year of Stock Market Ups and Downs - The InvestChronicle
Why CrowdStrike Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session - Benzinga
MEI Pharma rises on workforce reduction plan - XM
MEI Pharma Considering Strategic Alternatives; CEO Urso Steps Down - MarketWatch
MEIPMEI Pharma, Inc. Latest Stock News & Market Updates - StockTitan
Mei Pharma Inc Stock (MEIP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):